Tirzepatide
Published research and evidence base
Tirzepatide (LY3298176) is a fatty acid-modified synthetic peptide that agonises both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors from a single molecule. Receptor pharmacology published between 2018 and 2020 characterised it as imbalanced towards the GIP receptor and biased at the GLP-1 receptor, and rodent work linked that profile to reduced food intake and body weight. Clinical development proceeded through a phase 2 trial against dulaglutide, the SURPASS glycaemic-control programme in type 2 diabetes and the SURMOUNT body-weight programme in obesity, followed by dedicated trials in obstructive sleep apnoea, metabolic dysfunction-associated steatohepatitis and heart failure with preserved ejection fraction. SURPASS-CVOT, an active-comparator cardiovascular outcomes trial in more than 13,000 patients, reported in 2025. Tirzepatide is an approved prescription medicine for type 2 diabetes and for weight management in several jurisdictions, and gastrointestinal adverse events dominate the tolerability profile reported across the programme.
- Tirzepatide is a synthetic peptide that activates GIP and GLP-1 receptors.
- Human studies reported weight loss and blood sugar control in diabetes and obesity.
- Nearly all pivotal trials were manufacturer-funded; long-term data are limited.
43 studies · 29 since 2023 · newest 2026
- Studies cited
- 43
- Published 2023+
- 29
- Newest paper
- 2026
- Last reviewed
- Oct 2026
Recurring themes in the literature
- Dual GIP and GLP-1 receptor agonism from a single peptide
- Imbalanced receptor occupancy and biased GLP-1 receptor signalling
- Glycaemic control in type 2 diabetes (SURPASS programme)
- Dose-dependent body-weight reduction in obesity (SURMOUNT programme)
- Head-to-head comparison with selective GLP-1 receptor agonists
- Progression from prediabetes to type 2 diabetes
- Weight regain after treatment withdrawal
- Obstructive sleep apnoea and the apnoea-hypopnoea index
- Steatohepatitis resolution and hepatic fibrosis stage
- Heart failure with preserved ejection fraction and cardiovascular outcomes
- Body composition, muscle volume and muscle fat infiltration
- Gastrointestinal tolerability and gallbladder or biliary events
Compound identifiers
43 published studies.
Ordered by strength of study design, then by recency. Every entry links to its source record so the finding can be checked against the paper rather than taken on our word.
- 01Systematic review2026
Dose-response analysis of tirzepatide and acute pancreatitis: An international systematic review and quantitative meta-analysis of randomised trials.
Benny O, et al. · Pancreatology · systematic review and meta-analysis, 19 RCTs, n=15471
Acute pancreatitis occurred in 0.22% of trial participants, and head-to-head dose comparisons showed no significant difference in risk. All trials were industry-funded with short-to-moderate follow-up, limiting precision.
Reported safety finding. Acute pancreatitis was rare (0.22%) with no demonstrable dose-response, though precision was limited.
- 02Systematic review2025
Tirzepatide for adults living with obesity.
Franco JV, et al. · Cochrane Database Syst Rev · Cochrane systematic review, 9 RCTs, n=7111
Tirzepatide likely reduced body weight by about 16 percentage points versus placebo at 12-18 months, with the effect sustained at 3.5 years in one trial. Effects on MACE, mortality and quality of life were small or uncertain, non-serious adverse events may increase, and all trials were manufacturer-funded.
- 03Systematic review2023
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Zeng Q, et al. · Frontiers in Endocrinology · systematic review and meta-analysis of 9 randomised controlled trials, 9,871 participants with type 2 diabetes or obesity
Pancreatitis risk was not significantly increased relative to controls (RR 1.46, 95% CI 0.59-3.61). The composite of gallbladder or biliary disease was significantly more frequent than with placebo or basal insulin (RR 1.97, 95% CI 1.14-3.42), although the individual cholelithiasis and cholecystitis outcomes were not.
Reported safety finding. Increased composite risk of gallbladder or biliary disease versus placebo or basal insulin (RR 1.97, 95% CI 1.14-3.42)
- 04Systematic review2022
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Karagiannis T, et al. · Diabetologia · systematic review and meta-analysis of 7 randomised controlled trials, 6,609 participants with type 2 diabetes
Pooled HbA1c reduction was dose-dependent and superior to placebo, to GLP-1 receptor agonists and to basal insulin, with body-weight differences versus GLP-1 receptor agonists of 1.68 kg to 7.16 kg. Hypoglycaemia was not increased relative to placebo, while nausea, vomiting and diarrhoea were more frequent.
Reported safety finding. Nausea odds ratio 5.60 (95% CI 3.12-10.06) versus placebo at the highest dose, with higher discontinuation for adverse events at that dose regardless of comparator
- 05Human clinical2026
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.
Horn DB, et al. · Lancet · phase 3b RCT (SURMOUNT-MAINTAIN), n=378 randomised, 112 weeks
After 60 weeks of open-label tirzepatide, weight change from baseline to week 112 was -21.9% with continued maximum tolerated dose, -16.6% with a reduced dose and -9.9% after switching to placebo. Rescue therapy for regaining at least half the lost weight was needed in 8%, 25% and 67% respectively.
- 06Human clinical2026
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.
Zoungas S, et al. · Lancet Diabetes Endocrinol · prespecified exploratory analysis of RCT (SURPASS-CVOT), n=13165, median 4 years
The composite kidney outcome occurred in 6.0% with tirzepatide versus 7.6% with dulaglutide (HR 0.77), with similar reductions in low-to-moderate-risk and high-risk chronic kidney disease groups, driven by less new macroalbuminuria and slower eGFR decline.
- 07Human clinical2026
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial.
Del Prato S, et al. · Ann Intern Med · open-label phase 4 randomised trial (SURPASS-EARLY), n=794 adults with type 2 diabetes of at most 4 years' duration treated with metformin, 2 years, intensified conventional care comparator
At 2 years HbA1c fell by 1.99 percentage points with tirzepatide versus 1.32 with intensified conventional care (treatment difference -0.68, P < 0.001), with treatment differences of -8.0 kg in weight and -6.2 cm in waist circumference. Normoglycaemia (HbA1c <5.7%) was reached by 60.2% versus 24.0%, and gastrointestinal events were the most common adverse events in both groups.
- 08Human clinical2026
Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial.
Snaith JR, et al. · Diabetes Care · double-blind placebo-controlled phase 2 trial, n=24 adults with type 1 diabetes and BMI above 30 kg/m2, 12 weeks
Weight changed by -10.3 kg with tirzepatide versus -0.7 kg with placebo (treatment difference -8.7 kg, P < 0.0001), HbA1c differed by -0.4% versus placebo (P = 0.05), and insulin requirement fell by 35.1% relative to placebo. No significant adverse events were reported in either group.
- 09Human clinical2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
Lebwohl M, et al. · JAMA Dermatol · open-label phase 3b randomised trial, n=274 adults with moderate to severe plaque psoriasis and overweight or obesity, ixekizumab plus tirzepatide versus ixekizumab alone, 36-week primary endpoint within a 52-week trial
Complete skin clearance (PASI 100) together with at least 10% weight reduction occurred in 27.1% with the combination versus 5.8% with ixekizumab alone (P < .001), and PASI 100 alone in 40.6% versus 29.0% (P = .04). Gastrointestinal events were more frequent with the combination than with ixekizumab alone.
- 10Human clinical2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Merola JF, et al. · Arthritis Rheumatol · phase 3b randomised trial (TOGETHER-PsA), n=271 adults with active psoriatic arthritis and overweight or obesity, ixekizumab plus tirzepatide versus ixekizumab alone, 36-week primary endpoint within a 52-week trial
ACR50 response together with at least 10% weight reduction occurred in 31.7% with the combination versus 0.8% with ixekizumab alone (P < 0.001), and ACR50 alone in 33.5% versus 20.4% (P = 0.02). Safety profiles were reported as consistent with previous studies of each drug.
- 11Human clinical2026
Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
Yang Z, et al. · Diabetes Obes Metab · open-label randomised controlled trial in sixty overweight or obese Chinese women with polycystic ovary syndrome, tirzepatide plus metformin versus metformin alone, 16 weeks with pregnancy outcomes followed to week 48
Weight fell by 10.4 kg with the combination versus 1.7 kg with metformin alone (p < 0.001), with greater reductions in BMI and visceral adipose tissue and improvements in reproductive and metabolic parameters. Menstrual cycle recovery and total pregnancy rate were higher in the combination group (p = 0.013 and p = 0.014).
- 12Human clinical2026
Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
Crisafulli S, et al. · Ann Intern Med · population-based new-user active-comparator cohort study, adults with type 2 diabetes starting dulaglutide, subcutaneous semaglutide or tirzepatide in 2019-2024, 20 893 propensity-matched pairs for tirzepatide versus dulaglutide and 46 620 for tirzepatide versus semaglutide
The hazard ratio for a composite of acute pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation was 0.96 (95% CI 0.77 to 1.20) for tirzepatide versus dulaglutide and 1.07 (0.90 to 1.26) for tirzepatide versus semaglutide. The authors concluded that the three drugs had similar gastrointestinal safety profiles, noting possible residual confounding by glycaemic control and body mass index.
- 13Human clinical2025
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff AM, et al. · The New England Journal of Medicine · three-year analysis of the SURMOUNT-1 phase 3 trial, 1032 participants with obesity and prediabetes, 176 weeks on treatment plus a 17-week off-treatment period
Mean weight change at 176 weeks ranged from -12.3% to -19.7% across the dose groups versus -1.3% with placebo. Type 2 diabetes was diagnosed in 1.3% of treated participants compared with 13.3% on placebo (hazard ratio 0.07), and the authors reported that no new safety signals were identified.
- 14Human clinical2025
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer M, et al. · The New England Journal of Medicine · phase 3 double-blind placebo-controlled trial (SUMMIT), n=731 patients with heart failure with preserved ejection fraction and obesity, median follow-up 104 weeks
Cardiovascular death or a worsening heart-failure event occurred in 9.9% of treated patients versus 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41-0.95). The Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 19.5 points compared with 12.7 on placebo.
- 15Human clinical2025
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Nicholls SJ, et al. · The New England Journal of Medicine · double-blind active-comparator non-inferiority trial (SURPASS-CVOT), 13,165 adults analysed with type 2 diabetes and atherosclerotic cardiovascular disease, dulaglutide comparator
A primary composite event of cardiovascular death, myocardial infarction or stroke occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group (hazard ratio 0.92; P=0.003 for non-inferiority, P=0.09 for superiority). Gastrointestinal adverse events were more frequent in the tirzepatide group.
- 16Human clinical2025
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
Sattar N, et al. · The Lancet Diabetes & Endocrinology · post-hoc analysis of the SURPASS-3 MRI substudy, n=246 adults with type 2 diabetes with a valid week-52 scan, insulin degludec comparator
Pooled tirzepatide was associated with reductions at 52 weeks in thigh muscle fat infiltration (-0.36 percentage points), muscle volume (-0.64 L) and muscle volume Z score (-0.22), while insulin degludec was associated with modest weight and muscle-volume gain. Observed muscle-volume change was similar to UK Biobank population-based estimates for equivalent weight loss.
Reported safety finding. Measurable loss of thigh muscle volume alongside weight reduction, with the muscle volume Z score in the highest-dose group falling more than population-based estimates predicted
- 17Human clinical2025
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, et al. · N Engl J Med · phase 3b open-label RCT (SURMOUNT-5), n=751, 72 weeks, obesity without diabetes
Weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide, and waist circumference fell by 18.4 cm versus 13.0 cm. Gastrointestinal events were most common in both groups, mostly mild to moderate during dose escalation.
- 18Human clinical2025
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Hannon TS, et al. · Lancet · phase 3 RCT (SURPASS-PEDS), n=99, 30 weeks plus extension, ages 10-17 with type 2 diabetes
Tirzepatide lowered HbA1c by 2.23% versus a 0.05% rise with placebo at 30 weeks and reduced BMI, with effects sustained to 52 weeks. Gastrointestinal events were most common and mild to moderate; the safety profile was consistent with that in adults.
- 19Human clinical2025
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
Billings LK, et al. · Ann Intern Med · open-label phase 4 randomised trial (SURPASS-SWITCH), n=282 adults with type 2 diabetes inadequately controlled on lower doses of dulaglutide, 40 weeks, dulaglutide dose-escalation comparator
Switching to tirzepatide lowered HbA1c by 1.44% versus 0.67% with dulaglutide escalation (treatment difference -0.77%, P < 0.001) and reduced weight by 10.5 kg versus 3.6 kg. Serious adverse events were reported by 7.2% and 7.0% of participants respectively, and nausea and diarrhoea were the most common adverse events.
- 20Human clinical2025
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
Kadowaki T, et al. · Lancet Diabetes Endocrinol · double-blind placebo-controlled phase 3 trial (SURMOUNT-J), 267 Japanese adults with obesity disease without diabetes randomised (225 in the modified intention-to-treat population after one site was excluded), 72 weeks
Placebo-adjusted body-weight change at week 72 was -16.1% and -21.1% in the two tirzepatide dose groups (p<0.0001), and 94% and 96% reached at least 5% weight reduction versus 20% with placebo. Treatment-emergent adverse events, most commonly gastrointestinal, occurred in 84% and 86% of tirzepatide recipients versus 69% on placebo, while discontinuations due to adverse events were infrequent.
- 21Human clinical2025
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
Martin CK, et al. · Nat Med · randomised phase 1 trial, n=114 adults without diabetes with BMI 27 to 50 kg/m2, blinded tirzepatide or placebo plus an open-label liraglutide arm, 6 weeks
At week 3 tirzepatide reduced energy intake at an ad libitum lunch by 524.6 kcal versus placebo (P < 0.0001) and lowered overall appetite, food cravings and perceived hunger, without affecting volitional restriction of dietary intake. Brain activation to the aggregated category of highly palatable food photos did not differ significantly from placebo, although activation to high-fat, high-sugar food photos fell in several regions.
- 22Human clinical2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Look M, et al. · Diabetes Obes Metab · dual-energy X-ray absorptiometry substudy of the SURMOUNT-1 phase 3 RCT, n=160 adults with obesity or overweight (124 tirzepatide, 36 placebo), 72 weeks
Body weight, fat mass and lean mass changed by -21.3%, -33.9% and -10.9% with tirzepatide versus -5.3%, -8.2% and -2.6% with placebo (p < 0.001 for all). About 75% of the weight lost was fat mass and 25% lean mass in both arms, and these proportions were consistent across most sex and age subgroups.
- 23Human clinical2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Aronne LJ, et al. · JAMA · phase 3 randomised-withdrawal trial, 670 adults randomised after a 36-week open-label lead-in, 52-week double-blind period
Mean weight change from week 36 to week 88 was -5.5% with continued treatment versus +14.0% after a switch to placebo (difference -19.4%). At week 88, 89.5% of those continuing treatment had maintained at least 80% of the lead-in weight loss compared with 16.6% of those withdrawn.
- 24Human clinical2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra A, et al. · The New England Journal of Medicine · two phase 3 double-blind randomised controlled trials (SURMOUNT-OSA), adults with moderate-to-severe obstructive sleep apnoea and obesity, 52 weeks
The apnoea-hypopnoea index fell by 25.3 events per hour in the trial of participants not receiving positive airway pressure and by 29.3 events per hour among those receiving it, against reductions of roughly 5 events per hour on placebo. Hypoxic burden, high-sensitivity C-reactive protein and systolic blood pressure also improved.
- 25Human clinical2024
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
Loomba R, et al. · The New England Journal of Medicine · phase 2 dose-finding double-blind placebo-controlled trial (SYNERGY-NASH), n=190 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis, 52 weeks
Resolution of steatohepatitis without worsening of fibrosis was recorded in 44%, 56% and 62% of the three dose groups compared with 10% on placebo (P<0.001 for all three comparisons). The authors stated that larger and longer trials were needed to assess efficacy and safety further.
- 26Human clinical2024
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, et al. · JAMA · double-blind placebo-controlled phase 3 trial (SURMOUNT-CN), n=210 Chinese adults with obesity, or overweight with a weight-related comorbidity, without diabetes, 52 weeks
Mean body-weight change at week 52 was -13.6% and -17.5% in the two tirzepatide dose groups versus -2.3% with placebo (P < .001), and 87.7% and 85.8% versus 29.3% reached at least 5% weight reduction. Gastrointestinal events were the most frequent adverse events, mostly mild to moderate, with few leading to treatment discontinuation (<5%).
- 27Human clinical2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, et al. · The Lancet · phase 3 double-blind placebo-controlled trial, n=938 adults with obesity and type 2 diabetes, 72 weeks
Least-squares mean weight change at week 72 was -12.8% with 10 mg and -14.7% with 15 mg versus -3.2% with placebo. Between 79% and 83% of treated participants reached at least 5% weight reduction, compared with 32% on placebo.
- 28Human clinical2023
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.
Rosenstock J, et al. · JAMA · open-label phase 3b randomised trial (SURPASS-6), n=1428 adults with type 2 diabetes on basal insulin glargine, 52 weeks, prandial insulin lispro comparator
HbA1c fell by 2.1% with pooled tirzepatide versus 1.1% with insulin lispro (treatment difference -0.98%, P < .001), meeting non-inferiority and superiority, and body weight changed by -9.0 kg versus +3.2 kg. Hypoglycaemia occurred at 0.4 versus 4.4 events per patient-year, and nausea (14%-26%), diarrhoea (11%-15%) and vomiting (5%-13%) were the most common adverse events with tirzepatide.
- 29Human clinical2023
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial.
Gao L, et al. · Nat Med · open-label phase 3 randomised trial (SURPASS-AP-Combo), n=917 insulin-naive adults with type 2 diabetes on metformin with or without a sulphonylurea in China, South Korea, Australia and India (83.2% in China), 40 weeks, insulin glargine comparator
HbA1c fell by 2.24% to 2.49% across the three tirzepatide dose groups versus 0.95% with insulin glargine (all P < 0.001), and body weight fell by 5.0 kg to 7.2 kg against a 1.5 kg gain with glargine. The most common adverse events with tirzepatide were mild to moderate decreased appetite, diarrhoea and nausea, and no severe hypoglycaemia was reported.
- 30Human clinical2023
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Wadden TA, et al. · Nat Med · double-blind placebo-controlled phase 3 trial (SURMOUNT-3), n=579 adults with obesity or overweight without diabetes who had lost at least 5.0% of body weight during a 12-week intensive lifestyle run-in, 72 weeks
From randomisation to week 72, mean weight change was -18.4% with tirzepatide versus +2.5% with placebo (difference -20.8 percentage points, P < 0.001), and 87.5% versus 16.5% achieved at least 5% additional weight reduction. Gastrointestinal events were the most common adverse events with tirzepatide, mostly mild to moderate.
- 31Human clinical2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. · The New England Journal of Medicine · phase 3 double-blind randomised controlled trial (SURMOUNT-1), n=2539 adults with obesity or overweight without diabetes, 72 weeks
Mean percentage weight change at week 72 was -15.0%, -19.5% and -20.9% across the three dose groups versus -3.1% with placebo (P<0.001 for all comparisons). A reduction of at least 20% of body weight was recorded in 50% and 57% of the two highest dose groups compared with 3% on placebo.
- 32Human clinical2022
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D, et al. · JAMA · double-blind placebo-controlled phase 3 trial (SURPASS-5), n=475 adults with type 2 diabetes inadequately controlled on insulin glargine with or without metformin, 40 weeks
Added to insulin glargine, tirzepatide lowered HbA1c by 2.11% to 2.40% across the three dose groups versus 0.86% with placebo (P < .001), and body weight fell by 5.4 kg to 8.8 kg against a 1.6 kg gain on placebo. Diarrhoea (12%-21% vs 10%) and nausea (13%-18% vs 3%) were the most common adverse events, and premature treatment discontinuation reached 18% in the highest-dose group versus 3% on placebo.
- 33Human clinical2022
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
Inagaki N, et al. · Lancet Diabetes Endocrinol · double-blind phase 3 randomised trial (SURPASS J-mono), n=636 Japanese adults with type 2 diabetes, 52 weeks, dulaglutide comparator
HbA1c fell by 2.4 to 2.8 percentage points across the three tirzepatide dose groups versus 1.3 with dulaglutide (all p<0.0001), and body weight fell by 5.8 kg to 10.7 kg (7.8% to 13.9%) versus 0.5 kg with dulaglutide. Nausea affected 12% to 20% of tirzepatide recipients versus 8% on dulaglutide, and constipation 14% to 18% versus 11%.
- 34Human clinical2022
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
Kadowaki T, et al. · Lancet Diabetes Endocrinol · open-label phase 3 randomised dose-comparison trial without a placebo arm (SURPASS J-combo), n=443 Japanese adults with type 2 diabetes on a single oral antihyperglycaemic drug, 52 weeks
Safety was the primary endpoint: 77% of participants had at least one treatment-emergent adverse event, more often in the highest-dose group (84%) than in the two lower-dose groups (74% each), most commonly nasopharyngitis, nausea, constipation, diarrhoea and decreased appetite. HbA1c fell from about 8.5% at baseline to 5.6% to 6.0% and body weight fell by 5.1% to 13.2% across the dose groups, and no adjudication-confirmed deaths were reported.
- 35Human clinical2022
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, et al. · Lancet Diabetes Endocrinol · double-blind randomised phase 1 mechanistic trial, n=117 adults with type 2 diabetes at two centres in Germany, placebo and semaglutide comparators, 28 weeks
The clamp disposition index, which combines insulin secretion and insulin sensitivity, rose with tirzepatide versus placebo (treatment difference 1.92, p<0.0001) and by more than with semaglutide, reflecting greater gains in total insulin secretion rate and insulin sensitivity; glucose excursions and glucagon concentrations after a meal were also lower. Nausea occurred in 24% of tirzepatide, 30% of semaglutide and 25% of placebo recipients, and there were no deaths.
- 36Human clinical2021
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J, et al. · The Lancet · phase 3 double-blind placebo-controlled monotherapy trial, n=478 adults with type 2 diabetes naive to injectable therapy, 40 weeks
Mean HbA1c fell by 1.87% to 2.07% across the three dose groups compared with a 0.04% rise on placebo (all p<0.0001). Body-weight loss was dose-dependent at 7.0 kg to 9.5 kg, and no clinically significant or severe hypoglycaemia was reported on active treatment.
- 37Human clinical2021
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías JP, et al. · The New England Journal of Medicine · open-label phase 3 head-to-head trial, n=1879 adults with type 2 diabetes, 40 weeks, semaglutide 1 mg comparator
Estimated mean HbA1c change was -2.01, -2.24 and -2.30 percentage points across the three tirzepatide groups versus -1.86 with semaglutide, meeting both non-inferiority and superiority. Weight reduction was greater with tirzepatide, with estimated treatment differences of -1.9 kg, -3.6 kg and -5.5 kg.
- 38Human clinical2021
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Del Prato S, et al. · The Lancet · open-label phase 3 trial, n=1995 adults with type 2 diabetes and established or high cardiovascular risk, 52 weeks with treatment continued to a maximum of 104 weeks
HbA1c change at 52 weeks was -2.43% with 10 mg and -2.58% with 15 mg compared with -1.44% on insulin glargine. Adjudicated four-component major adverse cardiovascular events were not increased relative to glargine (hazard ratio 0.74, 95% CI 0.51-1.08), and hypoglycaemia was less frequent.
- 39Human clinical2021
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, et al. · Lancet · open-label phase 3 randomised trial (SURPASS-3), n=1444 insulin-naive adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor, 52 weeks, insulin degludec comparator
HbA1c fell by 1.93% to 2.37% across the three tirzepatide dose groups versus 1.34% with insulin degludec, and body weight fell by 7.5 kg to 12.9 kg with tirzepatide while it rose by 2.3 kg with degludec. Nausea (12-24%), diarrhoea (15-17%) and vomiting (6-10%) were more frequent with tirzepatide and hypoglycaemia less frequent, and discontinuation due to an adverse event was more common in the tirzepatide groups.
- 40Human clinical2020
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Frias JP, et al. · Diabetes Obes Metab · double-blind placebo-controlled randomised trial comparing three dose-escalation regimens, n=111 adults with type 2 diabetes, 12 weeks
HbA1c fell by 1.7% to 2.0% across the three tirzepatide regimens versus a 0.2% rise with placebo. Nausea occurred in 24.1% to 39.3% of tirzepatide recipients versus 7.7% on placebo, and the authors concluded that lower starting doses and smaller dose increments were associated with a more favourable side-effect profile.
- 41Human clinical2018
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Frias JP, et al. · The Lancet · phase 2 double-blind randomised trial, n=316 adults with type 2 diabetes, 26 weeks, placebo- and dulaglutide-controlled
Mean HbA1c change at 26 weeks ranged from -1.06% to -1.94% across the four dose groups, against -0.06% with placebo and -1.21% with dulaglutide. Mean body-weight change ranged from -0.9 kg to -11.3 kg, and the incidence of gastrointestinal events was dose-related, reaching 66.0% in the highest-dose group.
Reported safety finding. Dose-related gastrointestinal adverse events rising to 66.0% at the highest dose, versus 9.8% with placebo
- 42Animal in vivo2018
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, et al. · Molecular Metabolism · in vitro incretin receptor signalling assays, mice, and a phase 1 single- and multiple-ascending-dose programme in healthy subjects and adults with type 2 diabetes (142 dosed)
LY3298176 activated both GIP and GLP-1 receptor signalling in vitro and improved glucose tolerance in mice, where chronic administration lowered body weight and food intake more than a selective GLP-1 receptor agonist. In the phase 1b proof-of-concept cohort the 10 mg and 15 mg doses significantly reduced fasting serum glucose compared with placebo, and gastrointestinal events were the most frequent side effects.
- 43In vitro2020
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard FS, et al. · JCI Insight · receptor occupancy modelling and signalling assays in recombinant cell lines and primary islets
Occupancy calculations at clinically efficacious doses indicated greater engagement of the GIP receptor than of the GLP-1 receptor, described by the authors as an imbalanced mechanism of action. At the GLP-1 receptor the peptide favoured cAMP generation over beta-arrestin recruitment and drove less receptor internalisation than native GLP-1.
What this evidence does not establish.
Almost all of the pivotal literature was funded and conducted by the manufacturer, and independent replication outside that programme remains limited. SURPASS-CVOT established non-inferiority to dulaglutide for major adverse cardiovascular events but did not demonstrate superiority, and no placebo-controlled cardiovascular outcome trial has been published. Hepatic evidence rests on a phase 2 biopsy-based trial of 190 participants whose authors stated that larger and longer trials were needed. Data beyond the three-year SURMOUNT-1 analysis are not available, durability of effect after discontinuation was poor in the SURMOUNT-4 randomised-withdrawal design, and effects on all-cause mortality have not been established. Comparative evidence against other dual and triple incretin receptor agonists is sparse, muscle-composition findings come from a single post-hoc MRI substudy, and pancreatic and biliary safety estimates rest on meta-analyses with small numbers of events.
Common questions about the research.
- What is tirzepatide?
Tirzepatide (development code LY3298176) is a synthetic peptide with agonist activity at both the GIP and GLP-1 receptors. The material supplied by AKH BioLabs is a lyophilised research compound for laboratory use.
- What makes it a dual agonist rather than a GLP-1 agonist?
A GLP-1 agonist engages one incretin receptor. Tirzepatide engages two — the GIP receptor and the GLP-1 receptor — from a single molecule built on a GIP backbone, a design the cited discovery paper describes in detail.
- What does the published evidence base for tirzepatide consist of?
It spans receptor pharmacology and rodent work from 2018 to 2020, a phase 2 trial against dulaglutide, the phase 3 SURPASS programme in type 2 diabetes, the phase 3 SURMOUNT programme in obesity, dedicated outcome trials in obstructive sleep apnoea, steatohepatitis and heart failure with preserved ejection fraction, a large active-comparator cardiovascular outcomes trial, and systematic reviews pooling those randomised data.
The great majority of these trials were sponsored by the manufacturer.
- How large were the reported changes in HbA1c and body weight in the phase 3 trials?
In SURPASS-1 mean HbA1c fell by 1.87% to 2.07% across the dose groups against a 0.04% rise on placebo, and body weight fell by 7.0 kg to 9.5 kg. In SURMOUNT-1 the mean body-weight change at 72 weeks was -15.0% to -20.9% across dose groups compared with -3.1% on placebo.
Figures differ between trials because the populations, comparators and durations differ.
- Has tirzepatide been compared directly against a selective GLP-1 receptor agonist?
Yes. SURPASS-2 randomised 1,879 adults with type 2 diabetes to tirzepatide or semaglutide 1 mg over 40 weeks and reported tirzepatide as non-inferior and superior on HbA1c change, with greater weight reduction. SURPASS-CVOT used dulaglutide as the active comparator in a cardiovascular outcomes setting.
Both comparisons were open-label or active-controlled rather than placebo-controlled.
- What have the cardiovascular outcome trials reported?
SURPASS-CVOT randomised 13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease against dulaglutide and reported a primary composite event in 12.2% versus 13.1%, meeting non-inferiority but not superiority. The SUMMIT trial in heart failure with preserved ejection fraction and obesity reported a hazard ratio of 0.62 for cardiovascular death or worsening heart failure against placebo.
Neither result establishes a placebo-controlled cardiovascular benefit in the wider type 2 diabetes population.
- Which adverse events recur most consistently across the trials?
Gastrointestinal events - nausea, diarrhoea, vomiting and decreased appetite - are the most frequently reported in every programme, are dose-related, and cluster during the escalation period. A meta-analysis of nine randomised trials reported an increased composite risk of gallbladder or biliary disease relative to placebo or basal insulin, while pancreatitis risk was not significantly raised.
Hypoglycaemia was not increased relative to placebo in the pooled analyses.
- Does the literature extend beyond type 2 diabetes and obesity?
It does. Published randomised trials cover obstructive sleep apnoea with obesity, metabolic dysfunction-associated steatohepatitis with stage F2 or F3 fibrosis, heart failure with preserved ejection fraction and obesity, and progression from prediabetes to type 2 diabetes.
The steatohepatitis evidence is phase 2 and biopsy-based in 190 participants; the sleep apnoea and heart failure evidence is phase 3.
- What happened when treatment was stopped in the published trials?
SURMOUNT-4 used a randomised-withdrawal design: after a 36-week lead-in, participants switched to placebo regained weight, with a mean change of +14.0% from week 36 to week 88 against -5.5% for those who continued. In the three-year SURMOUNT-1 analysis, 2.4% of previously treated participants had type 2 diabetes after a 17-week off-treatment period versus 13.7% of the placebo group.
Durability of effect after discontinuation is therefore limited in the published record.
- What has been reported about effects on muscle mass?
A post-hoc analysis of the SURPASS-3 MRI substudy measured thigh muscle composition in 246 participants at 52 weeks and reported reductions in muscle volume, muscle volume Z score and muscle fat infiltration alongside weight loss. The observed muscle-volume change was broadly similar to UK Biobank population-based estimates for comparable weight reduction.
This remains a single exploratory analysis and has not been replicated in a prespecified trial.
Available from our catalog
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no study summarised here should be read as a recommendation.